MX2013002660A - Heteroarilmetilamidas. - Google Patents

Heteroarilmetilamidas.

Info

Publication number
MX2013002660A
MX2013002660A MX2013002660A MX2013002660A MX2013002660A MX 2013002660 A MX2013002660 A MX 2013002660A MX 2013002660 A MX2013002660 A MX 2013002660A MX 2013002660 A MX2013002660 A MX 2013002660A MX 2013002660 A MX2013002660 A MX 2013002660A
Authority
MX
Mexico
Prior art keywords
heteroarylmethyl
amides
diseases
hdl
prophylaxis
Prior art date
Application number
MX2013002660A
Other languages
English (en)
Inventor
Paul Hebeisen
Stephan Roever
Hugues Matile
Matthew Wright
Sannah Zoffmann Jensen
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2013002660A publication Critical patent/MX2013002660A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

La presente invención se refiere a compuestos de la fórmula (Ver Formula) en la que A1, A2, A3 y de R1 a R8 tienen los significados definidos en la descripción y a sus sales farmacéuticamente aceptables, a su obtención, a composiciones farmacéuticas que los contienen y a su utilización como medicamentos para el tratamiento y/o profilaxis de enfermedades que pueden tratarse con agentes que elevan el nivel del colesterol HDL, por ejemplo en especial la dislipidemia, la aterosclerosis y las enfermedades cardiovasculares.
MX2013002660A 2010-09-09 2011-09-06 Heteroarilmetilamidas. MX2013002660A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10175984 2010-09-09
PCT/EP2011/065341 WO2012032018A1 (en) 2010-09-09 2011-09-06 Heteroarylmethyl amides

Publications (1)

Publication Number Publication Date
MX2013002660A true MX2013002660A (es) 2013-04-09

Family

ID=44359517

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013002660A MX2013002660A (es) 2010-09-09 2011-09-06 Heteroarilmetilamidas.

Country Status (14)

Country Link
US (2) US8729105B2 (es)
EP (1) EP2613785B1 (es)
JP (1) JP5667297B2 (es)
KR (1) KR101546595B1 (es)
CN (1) CN103118680B (es)
AR (1) AR082914A1 (es)
BR (1) BR112013005622A2 (es)
CA (1) CA2808665A1 (es)
ES (1) ES2548035T3 (es)
HK (1) HK1181655A1 (es)
MX (1) MX2013002660A (es)
RU (1) RU2013113118A (es)
TW (1) TW201217367A (es)
WO (2) WO2012031817A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL1037569C2 (en) * 2009-12-18 2011-06-21 Eurovet Animal Health B V Crystalline pimobendan, process for the preparation thereof, pharmaceutical composition and use.
US9321727B2 (en) * 2011-06-10 2016-04-26 Hoffmann-La Roche Inc. Pyridine derivatives as agonists of the CB2 receptor
TWI644016B (zh) * 2012-11-02 2018-12-11 艾克頌美孚上游研究公司 用於在化學計量廢氣再循環氣渦輪系統中以氧化劑－稀釋劑混合進行擴散燃燒之系統及方法
LT2928882T (lt) 2012-12-07 2017-03-27 F. Hoffmann-La Roche Ag Pirazino dariniai kaip cb2 receptoriaus agonistai
LT2928868T (lt) * 2012-12-07 2017-10-25 F. Hoffmann-La Roche Ag Piridin-2-amidai, tinkami naudoti kaip cb2 agonistai
WO2014086705A1 (en) * 2012-12-07 2014-06-12 F. Hoffmann-La Roche Ag Novel pyridine derivatives
MY179412A (en) 2012-12-07 2020-11-05 Hoffmann La Roche Pyridine-2-amides useful as cb2 agonists
PE20161407A1 (es) * 2014-04-04 2016-12-28 Hoffmann La Roche Piridina 5,6 disustituida -2-carboxamidas como agonistas del receptor canabinoide
SG11201608108SA (en) * 2014-04-04 2016-10-28 Hoffmann La Roche Pyridine-2-amides useful as cb2 agonists
US10538491B2 (en) 2015-03-16 2020-01-21 Vanderbilt University 4,5-substituted picolinamide and picolinonitrile metabotropic glutamate receptor 2 negative allosteric modulators
WO2018234284A1 (en) * 2017-06-20 2018-12-27 F. Hoffmann-La Roche Ag PYRIDINE DERIVATIVES
US20200085810A1 (en) 2018-07-26 2020-03-19 Hoffmann-La Roche Inc. Compounds for use in treating kidney disorders
EP4096656A4 (en) * 2020-02-02 2023-07-12 Ramot at Tel-Aviv University Ltd. NOVEL ACTIVATORS OF ATP-BINDING CASSETTE PROTEIN TYPE 1 (ABCA1) AND THERAPEUTIC USES THEREOF
CN113390984B (zh) * 2021-05-31 2022-09-16 常州沃腾化工科技有限公司 环丁醇和环丙甲醇的气相分离分析方法
US11814354B2 (en) * 2021-09-08 2023-11-14 River 3 Renal Corp. Solid forms

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6555323B2 (en) * 2000-02-08 2003-04-29 Pfizer Inc. Assay for ABCA1
SE0104332D0 (sv) * 2001-12-19 2001-12-19 Astrazeneca Ab Therapeutic agents
GB0222495D0 (en) * 2002-09-27 2002-11-06 Glaxo Group Ltd Compounds
WO2006106054A1 (en) * 2005-04-06 2006-10-12 F. Hoffmann-La Roche Ag Pyridine-3-carboxamide derivatives as cb1 inverse agonists
US7629346B2 (en) * 2006-06-19 2009-12-08 Hoffmann-La Roche Inc. Pyrazinecarboxamide derivatives as CB1 antagonists
ES2344128T3 (es) * 2006-10-04 2010-08-18 F. Hoffmann-La Roche Ag Derivados de pirazina-2-carboxamida como moduladores de receptores cb2.
BRPI0717845A2 (pt) * 2006-10-04 2015-06-16 Hoffmann La Roche Uso de compostos, composições farmacêuticas e métodos para o tratamento e/ou profilaxia de enfermidades que podem ser tratadas com agentes de elevação de colesterol-hdl e compostos
US7897621B2 (en) 2008-03-31 2011-03-01 Hoffmann-La Roche Inc. 2-trifluoromethylnicotinamide derivatives as HDL-cholesterol raising agents
US8088920B2 (en) 2008-03-31 2012-01-03 Hoffmann-La Roche Inc. 3-trifluoromethyl-pyrazine-2-carboxylic acid amide derivatives as HDL-cholesterol raising agents
WO2010051188A1 (en) * 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. P2x3, receptor antagonists for treatment of pain
UA107088C2 (xx) 2009-09-11 2014-11-25 5-(3,4-дихлорфеніл)-n-(2-гідроксициклогексил)-6-(2,2,2-трифторетокси)нікотинамід і його солі як засоби, що підвищують концентрацію лвщ холестерину
US8669254B2 (en) * 2010-12-15 2014-03-11 Hoffman-La Roche Inc. Pyridine, pyridazine, pyrimidine or pyrazine carboxamides as HDL-cholesterol raising agents

Also Published As

Publication number Publication date
KR20130081288A (ko) 2013-07-16
JP5667297B2 (ja) 2015-02-12
EP2613785A1 (en) 2013-07-17
US9090599B2 (en) 2015-07-28
TW201217367A (en) 2012-05-01
BR112013005622A2 (pt) 2016-05-03
WO2012032018A1 (en) 2012-03-15
CN103118680A (zh) 2013-05-22
CA2808665A1 (en) 2012-03-15
KR101546595B1 (ko) 2015-08-21
CN103118680B (zh) 2015-12-16
EP2613785B1 (en) 2015-07-29
US20120065212A1 (en) 2012-03-15
JP2013537173A (ja) 2013-09-30
ES2548035T3 (es) 2015-10-13
US8729105B2 (en) 2014-05-20
US20140194436A1 (en) 2014-07-10
HK1181655A1 (zh) 2013-11-15
WO2012031817A1 (en) 2012-03-15
AR082914A1 (es) 2013-01-16
RU2013113118A (ru) 2014-10-20

Similar Documents

Publication Publication Date Title
MX2013002660A (es) Heteroarilmetilamidas.
MX2013004759A (es) Compuestos de oxima como agentes de elevacion de colesterol de lipoproteina de alta densidad (hdl).
IN2014DN09434A (es)
IN2015DN01156A (es)
PH12014501967B1 (en) Benzodioxanes in combination with other actives for inhibiting leukotriene production
PH12015501385A1 (en) Autotaxin inhibitors
MY188960A (en) Cyclic boronic acid ester derivatives and therapeutic uses thereof
MX2015007710A (es) Indanilcarboxamidas difluorometil-nicotinicas.
MX338114B (es) Inhibidores de arginasa y sus aplicaciones terapeuticas.
IN2012DN01233A (es)
WO2014028600A3 (en) 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
GB2511685A (en) Muscarinic m1 receptor agonists
MX344238B (es) Compuestos de tetrazol y métodos para preparar y usar los mismos.
MX343706B (es) Derivados heterocíclicos novedosos.
NZ628294A (en) Compositions and methods of use of phorbol esters for the treatment of stroke
PH12014501514A1 (en) New azetidine derivatives, pharmaceutical compositions and uses thereof
IN2015DN01119A (es)
MY157429A (en) Trpm8 antagonists and their use in treatments
MY167898A (en) Co-crystals and salts of ccr3-inhibitors
MX2014001599A (es) 3,4-dihidro-1h-[1,8]naftiridinosas sustituidas con piperidinilo antibacterianas.
MX342947B (es) Tratamiento de diabetes tipo 2.
MX2014015884A (es) Compuestos antivirales.
IN2012DN00763A (es)
MX2010009999A (es) Derivados de amidas del acido 3-trifluorometil-pirazina-2-carboxil ico como agentes para aumentar el colesterol de lipoproteinas de alta densidad.
MX2010010000A (es) Derivados de 2-trifluorometilnicotinamida como agentes para aumentar el colesterol de lipoproteinas de alta densidad.

Legal Events

Date Code Title Description
FG Grant or registration